米非司酮联合亮丙瑞林治疗子宫肌瘤的疗效研究

目的 探讨米非司酮联合亮丙瑞林治疗子宫肌瘤的临床疗效。方法 以回顾性研究的方法选取2015年7月-2018年7月漯河市郾城区中医院88例子宫肌瘤患者为研究对象，根据不同的给药方法将受试者进行分组，其中对照组44例患者接受亮丙瑞林治疗，观察组44例患者在对照组的基础上联合米非司酮治疗，两组均连续治疗3个月。比较两组患者的临床疗效、治疗前后各性激素与血清细胞因子水平变化以及子宫与肌瘤体积变化。结果 观察组的治疗总有效率为93.18%，显著高于对照组的77.27%（P<0.05）。治疗后两组患者孕激素（P）、雌二醇（E2）、促卵泡生长激素（FSH）、黄体生成激素（LH）等各性激素水平及基质金属蛋白酶-9（MMP-9）、胰岛素样生长因子（IGF-1）、肿瘤坏死因子-α（TNF-α）、表皮细胞生长因子（EGF）、超敏C反应蛋白（hs-CRP）等细胞因子水平较治疗前均显著降低（P<0.05），且观察组均显著低于对照组（P<0.05）。治疗后两组患者的子宫及肌瘤体积较治疗前均显著减小（P<0.05），且观察组显著小于对照组（P<0.05）。结论 米非司酮联合亮丙瑞林可有效降低各性激素及血清细胞因子水平，改善患者的临床症状及体征，疗效确切，在子宫肌瘤治疗中具有较高的应用价值。

Efficacy study of mifepristone combined with leuprolide on patients with uterine fibroids

Objective To explore clinical efficacy of mifepristone combined with leuprolide on patients with uterine fibroids.Methods Selecting the method of retrospective study,88 patients with uterine fibroids were selected as the subjects in our hospital from July 2015 to July 2018,Subjects are grouped according to different methods of administration.44 patients in the control group were treated with mifepristone,44 patients in the experimental group on the basis of this combination of leuprolide.The clinical efficacy,the changes of sex hormones and serum cytokines levels,and the changes of uterus and fibroid volume before and after treatmentwere compared between the two groups.Results The total effective rate of the study group were significantly higher than the control group (P<0.05).After treatment,the sex hormones and serum cytokines levels of the two groups were significantly reduced than those before treatment,and the study group was significantly lower than the control group (P<0.05).After treatment,the uterus and fibroid volume in the two groups were significantly reduced than those before treatment,and the study group was smaller than the control group (P<0.05).Conclusion Mifepristone combined with leuprolide can effectively reduce sex hormones and serum cytokines levels,improve the clinical symptoms and signs of patients,the curative effect is exact,which has high application value in the treatment of uterine fibroids.